IgGenix emerges from stealth with $10 mil­lion Se­ries A hop­ing to re-en­gi­neer al­ler­gic cas­cade

A lit­tle over six months af­ter the FDA ap­proved the first treat­ment for peanut al­ler­gies, a new biotech has emerged hop­ing to break through in a field that’s seen vir­tu­al­ly no in­no­va­tion.

IgGenix came out of stealth mode Tues­day morn­ing, an­nounc­ing a $10 mil­lion Se­ries A round to get the com­pa­ny start­ed. The Cal­i­for­nia-based biotech aims to fo­cus not just on peanuts, but all types of food al­ler­gies and re­lat­ed se­ri­ous con­di­tions by de­vel­op­ing a plat­form that can in­ter­fere with the al­ler­gic cas­cade. Fi­nanc­ing was led by Khosla Ven­tures and joined by Park­er Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER